Therapiedeeskalation bei ANCA-assoziierten Vaskulitiden

Translated title of the contribution: De-escalation of therapy in ANCA-associated vasculitides

S. Schinke, G. Riemekasten, P. Lamprecht*

*Corresponding author for this work
1 Citation (Scopus)


Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) require a differentiated therapeutic approach depending on the degree of organ dysfunction and disease activity. In organ dysfunction and life-threatening AAV cyclophosphamide and rituximab are recommended for the induction of remission. For remission induction with a lack of organ dysfunction and non-life-threatening AAV, methotrexate or mycophenolate mofetil are recommended. For remission maintenance therapy azathioprine or methotrexate are used. In the case of contraindications, intolerance or previous failure of azathioprine and methotrexate treatment, rituximab, leflunomide or mycophenolate mofetil may be used as alternatives. Maintenance therapy is usually continued for at least 2 years. De-escalation of therapy requires continuous clinical monitoring while the glucocorticoid medication and immunosuppressive therapy is tapered; however, every de-escalation of therapy carries a risk of relapse.

Translated title of the contributionDe-escalation of therapy in ANCA-associated vasculitides
Original languageGerman
JournalZeitschrift fur Rheumatologie
Issue number1
Pages (from-to)15-20
Number of pages6
Publication statusPublished - 01.02.2017

Research Areas and Centers

  • Academic Focus: Center for Infection and Inflammation Research (ZIEL)


Dive into the research topics of 'De-escalation of therapy in ANCA-associated vasculitides'. Together they form a unique fingerprint.

Cite this